西班牙HIV-2感染者使用整合酶抑制剂的临床经验
该回顾性观察研究分析了西班牙HIV-2队列中使用整合酶链转移抑制剂(INSTI)的44例患者,中位随访13个月后,初治患者HIV-2病毒血症不可测比例为89%,经治患者为65.4%,CD4分别增加82和126 cells/mm3;15例治疗失败者中12例出现INSTI耐药突变。
要点
- INSTI方案对HIV-2初治和经治患者均有效,初治病毒学抑制率更高。
- 治疗失败患者中INSTI耐药突变常见,以N155H、Q148H/R、Y143C/G为主。
- HIV-2治疗选择有限,需关注INSTI耐药对后续方案的影响。
核心结论
- 基于INSTI的组合是HIV-2感染者有效且安全的治疗选择,但失败患者易选择出INSTI耐药突变,进一步减少有限的治疗选择。
研究设计与样本
- 回顾性观察研究,分析西班牙HIV-2队列截至2017年12月记录的354例HIV-2感染者中使用INSTI的44例患者。
主要发现
- 44例中18例为一线治疗,26例为其他抗逆转录病毒方案失败后使用INSTI。
- 中位随访13个月,初治患者HIV-2病毒血症不可测比例为89%,经治患者为65.4%。
- CD4计数分别增加82和126 cells/mm3(初治和经治患者)。
- 15例治疗失败(初治2例,经治13例),12例检出INSTI耐药突变:N155H(5例)、Q148H/R(3例)、Y143C/G(3例)、R263K(1例)。
临床怎么用
- 可考虑INSTI为基础方案治疗HIV-2感染,但需密切监测病毒学和耐药。
局限性
- 回顾性观察性设计,样本量有限(44例),随访时间较短(中位13个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HIV-2 is a neglected virus despite estimates of 1-2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. METHODS: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with integrase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modalities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. RESULTS: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126 cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). CONCLUSIONS: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individuals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.
引用
- Requena S, Lozano AB, Caballero E, et al. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. J Antimicrob Chemother. 2019. PMID: 30753573. doi:10.1093/jac/dkz007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。